---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-194863"
form_type: "8-K"
ticker: "TEM"
cik: "0001717115"
company_name: "Tempus AI, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:26:39.318160+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tempus Q2 revenue $166M, up 25% YoY; guides FY2024 revenue ~$700M

## Summary
- Revenue $166.0M (+25% YoY); data licensing grew 40% YoY; genomics revenue $112.3M (+22.2%).
- Net loss ($552.2M) largely from $493.1M stock compensation and payroll taxes tied to IPO.
- Adjusted EBITDA ($31.2M), improved $12.7M QoQ from Q1; Non-GAAP genomics margin 49.4% (+50bps).
- FY2024 revenue guidance ~$700M (~32% growth); adjusted EBITDA guided at ~($105M), improvement of ~$50M.
- Launched MRD assays, JV with SoftBank for Japan, FDA 510(k) for ECG-AF device, CMS ADLT status for xT CDx.

## SEC filing metadata
- accession: 0001193125-24-194863
- form_type: 8-K
- ticker: TEM
- cik: 0001717115
- company_name: Tempus AI, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1717115/000119312524194863/0001193125-24-194863-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1717115/000119312524194863/d878812d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-194863
- JSON: https://secwatch.observer/filing/0001193125-24-194863.json
- Plain text: https://secwatch.observer/filing/0001193125-24-194863.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.